R&D executives searching for open #innovation networks

Big Pharma companies changed up their R&D programs in 2011 – Pfizer pursued a major reduction, AstraZeneca, GlaxoSmithKline and other rebooting their programs. This year, some companies have been trying to outsource their development. There has also been a shift from west to east in R&D. Attracted by much lower costs, Big Pharma companies are looking at China and other …

#Celator Pharmaceuticals raising $5 million for #cancer treatments

CPX-351, a drug therapy for acute myeloid leukemia, has been raised by the U.S. Food and Drug Administration, FDA, to orphan drug status. Now with seven years market exclusivity in the U.S, Celator Pharmaceuticals will continue through to phase 2 clinical trials. According to medcitynews.com, its goals involve a fund of $5 million, and $2.57m of this target has been …

#Alexion Pharma acquires #Enobia Pharma

Alexion Pharmaceuticals acquired privately held Enobia Pharma Corp. expanding its presence in the orphan drug scientific market and first potential treatment for patients with Hypophosphatasia. Much of Alexion’s efforts have focused on educating physicians about such rare disorders, which can take years to be properly diagnosed, as opposed to focusing on the drug. Enobia focuses on development of therapies to …